What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?

Name: What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?
Uploaded: 2020-06-09T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois